EMERGENT BIOSOLUTIONS INC. COMMON STOCK

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

24 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

08 Nov 2023 16:38:16 By Nasdaq GlobeNewswire

UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023

30 Oct 2023 15:45:13 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

19 Oct 2023 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

02 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

30 Aug 2023 04:59:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

08 Aug 2023 15:31:58 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

08 Aug 2023 06:15:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

31 Jul 2023 15:05:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

20 Jul 2023 17:03:20 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces CEO Transition

27 Jun 2023 06:55:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

15 May 2023 06:58:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

11 May 2023 05:30:00 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For First Quarter 2023

09 May 2023 15:05:02 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

19 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment

29 Mar 2023 08:48:20 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022

27 Feb 2023 15:42:44 By Nasdaq GlobeNewswire

Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use

15 Feb 2023 16:19:50 By Nasdaq GlobeNewswire

Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million

15 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

06 Feb 2023 15:05:00 By Nasdaq GlobeNewswire